Sarepta Therapeutics
SRPT
372 hedge funds and large institutions have $8.48B invested in Sarepta Therapeutics in 2019 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 142 increasing their positions, 115 reducing their positions, and 35 closing their positions.
106% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 35
28% more call options, than puts
Call options by funds: $363M | Put options by funds: $283M
23% more repeat investments, than reductions
Existing positions increased: 142 | Existing positions reduced: 115
14% more capital invested
Capital invested by funds: $7.46B → $8.48B (+$1.02B)
11% more funds holding
Funds holding: 336 → 372 (+36)
1.01% less ownership
Funds ownership: 97.5% → 96.48% (-1%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$112M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$106M |
| 3 |
O
OppenheimerFunds
New York
|
+$82.5M |
| 4 |
Sands Capital Management
Arlington,
Virginia
|
+$67.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$50.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$108M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$90M |
| 3 |
BlackRock
New York
|
-$84.6M |
| 4 |
FAM
Fred Alger Management
New York
|
-$77.5M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$43.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DWM
401
Doyle Wealth Management
St. Petersburg,
Florida
| – | -$5K | -50 | Closed |
|
402
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$3K | -26 | Closed |
|
|
IIM
403
Ipswich Investment Management
Beverly,
Massachusetts
| – | -$3K | -25 | Closed |
|
|
PHK
404
Point72 Hong Kong
Hong Kong
| – | -$1K | -9 | Closed |
|
|
TWA
405
TCI Wealth Advisors
Tucson,
Arizona
| – | +$386 | +3 | New |
|
SRPT Hedge Fund Activity: Q1 2019 in Review
372 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2019, worth a combined $8.48B — up 14% from $7.46B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new SRPT positions and 35 closed out — a net gain of 37 holders — while 142 added to existing stakes and 115 trimmed.
The largest buyer was Ameriprise, adding an estimated $112M. The largest seller was T. Rowe Price Associates, cutting an estimated $108M.
- 372 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2019, up from 336 in Q4 2018.
- Funds reported $8.48B of Sarepta Therapeutics stock for Q1 2019, up 14% quarter-over-quarter.
- 72 funds opened new Sarepta Therapeutics positions in Q1 2019 and 35 closed out, a net change of +37 holders.
- The largest Sarepta Therapeutics buyer in Q1 2019 was Ameriprise, an estimated $112M added.
- The largest Sarepta Therapeutics seller in Q1 2019 was T. Rowe Price Associates, an estimated $108M sold.
Based on aggregated 13F filings for Q1 2019.